8 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
Follow Sleep Initiation and Maintenance Disorders: new trials by email Literature Review of Sleep Initiation and Maintenance Disorders trials Research Report on Sleep Initiation and Maintenance Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder suvorexant (SUVO), Placebo - Methamphetamine Use Disorder | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 7 | 2023-03-09 | 2025-04-29 |
| Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth Bryophyllum 50% chewable tablets, Placebo - Preterm Labor, Anxiety | Phase 2 | Terminated | Christian Haslinger | 60 | 2022-07-12 | 2023-12-13 |
| Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence Suvorexant 20 mg, placebo - Insomnia, Alcohol Use Disorder | Phase 2 | Terminated | The Florey Institute of Neuroscience and Mental Health | 22 | 2019-08-26 | 2023-02-15 |
| Investigation of the Efficacy and Safety of CHI-921 in Insomnia. CHI-921, Placebo - Insomnia | Phase 2 | Terminated | Canopy Growth Corporation | 21 | 2019-03-21 | 2020-10-05 |
| Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients Cyclobenzaprine - Sleep Initiation and Maintenance Disorders, Pain | Phase 2 | Terminated | Lynn Henry | 2 | 2013-08-01 | 2016-04-20 |
| Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Gabapentin, placebo - Neurologically Impaired, Irritable Mood | Phase 2 | Terminated | Gillette Children's Specialty Healthcare | 2 | 2012-04-01 | 2019-08-02 |
| Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs Adipiplon, Placebo, Ambien CR - Primary Insomnia | Phase 2 | Terminated | Neurogen Corporation | 84 | 2008-05-01 | 2008-07-22 |
| Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED) MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia | Phase 2 | Terminated | H. Lundbeck A/S | 50 | 2005-11-01 | 2015-01-14 |
Alcoholism (1) · Anxiety Disorders (1) · Breast Neoplasms (1) · Chronic Pain (1) · Marijuana Abuse (1) · Obstetric Labor, Premature (1) · Pain (1) · Signs and Symptoms, Digestive (1)
Dyssomnias (8) · Mental Disorders (8) · Nervous System Diseases (8) · Sleep Disorders, Intrinsic (8) · Sleep Wake Disorders (8) · Chemically-Induced Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Substance-Related Disorders (2) · Alcohol-Related Disorders (1) · Breast Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Neoplasms (1) · Neoplasms by Site (1)
suvorexant (2) · Duration of Therapy (1) · Gabapentin (1) · Zolpidem (1) · adipiplon (1) · cyclobenzaprine (1) · gaboxadol (1)
Canopy Growth Corporation (1) · Christian Haslinger (1) · Gillette Children's Specialty Healthcare (1) · H. Lundbeck A/S (1) · Lynn Henry (1) · Neurogen Corporation (1) · The Florey Institute of Neuroscience and Mental Health (1) · The University of Texas Health Science Center, Houston (1)
United States (4) · Australia (1) · Canada (1) · Switzerland (1)
Andrew Lawrence (1) · Dr M Ware, MD (1) · Heather Webber, PhD (1) · Norah L Henry, MD, PhD (1) · Scott Schwantes, MD (1) · Yvonne Bonomo (1)